Health & Fitness
Tue, May 11, 2010Mon, May 10, 2010Sun, May 9, 2010Sat, May 8, 2010Fri, May 7, 2010Thu, May 6, 2010Mon, January 11, 2010Sat, January 9, 2010Fri, January 8, 2010Thu, January 7, 2010Wed, January 6, 2010Tue, January 5, 2010Mon, January 4, 2010Thu, December 31, 2009Wed, December 30, 2009Tue, December 29, 2009Mon, December 28, 2009Thu, December 24, 2009Wed, December 23, 2009Tue, December 22, 2009Mon, December 21, 2009Cardiogenesis Corporation to Present at OneMedForum 2010 Emerging Company Finance Forum
Published in Health and Fitness on Wednesday, January 6th 2010 at 4:50 GMT by Market Wire
Cardiogenesis Corporation to Present at OneMedForum 2010 Emerging Company Finance Forum -- IRVINE, Calif., Jan. 6 /PRNewswire-FirstCall/ --
Cardiogenesis Corporation to Present at OneMedForum 2010 Emerging Company Finance Forum
IRVINE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) today announced that it is scheduled to present at the 2010 OneMedPlace Finance Forum to be held at the Sir Francis Drake Hotel in San Francisco. Executive Chairman, Paul J. McCormick will present a 30-minute corporate overview next Tuesday, January 12, 2010 at 3:00 pm Pacific time (6:00 pm Eastern time) and meet one-on-one with investors during the conference.
The annual OneMedForum provides an opportunity for the most promising emerging healthcare and life science companies to present to and interact with a diverse group of global investors and partners. The forum is held at the Sir Francis Drake Hotel in San Francisco, during the Healthcare community's largest gathering of the year - the JP Morgan Healthcare Conference.
Throughout the two days, over 100 CEOs will present their company to 500+ OneMedForum guests. In attendance will be institutional investors, venture capitalists, private investors, business development executives, and industry executives from across the healthcare landscape.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. For more information on the company and its products, please visit the Cardiogenesis company website at [ http://www.cardiogenesis.com ] or the direct to patient website at [ http://www.heartofnewlife.com ].
SOURCE Cardiogenesis Corporation
RELATED LINKS
[ http://www.cardiogenesis.com ]
[ http://www.heartofnewlife.com ]
